Athenex

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athenex - China API Business engages in Active Pharmaceutical Ingredient (API) manufacturing operations.

BUFFALO, N.Y., Sept.  11, 2019  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its partner, Guangzhou Xiangxue Pharmaceutical Co., Ltd., initiated a Phase I study in China of KX2-361 (formerly known as KX-02) oral treating advanced malignant solid tumors.

Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical

紐約水牛城, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX) 今天宣佈委任 Daniel Lang，MD 成為Axis Therapeutics Limited 的總裁兼Athenex，Inc 的企業發展高級總監。Athenex, Inc. 是一家國際生物製藥公司，致力於發現、開發及商業化癌症與相關疾病的創新療法。

Athenex 宣布任命 Daniel Lang MD 領導 TCR-T 免疫治療操作和支持企業發展策略

BUFFALO, N.Y., Sept.  04, 2019  (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Daniel Lang, MD, as President of Axis Therapeutics Limited and Senior Director of Corporate Development at Athenex, Inc.

Athenex Announces Appointment of Daniel Lang MD to Lead TCR-T Immunotherapy Operations and Support Corporate Development Strategy

CEO and Chairman of the Board of Athenex Inc (30-Year Financial, Insider Trades) Johnson Yiu Nam Lau (insider trades) bought 5,000 shares of ATNX on 08/23/2019 at an average price of $14.98 a share.

Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $74,900 of Shares

General Electric

Lockheed Martin

Mastercard

Company insiders invest in Mastercard, Lockheed Martin, General Electric and Athenex.

Top Insider Buys Highlight for the Week of Aug. 16

CEO and Chairman of the Board of Athenex Inc (30-Year Financial, Insider Trades) Johnson Yiu Nam Lau (insider trades) bought 10,000 shares of ATNX on 08/15/2019 at an average price of $14.9 a share.

Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $149,000 of Shares

Athenex reported positive results in a phase 3 study using oral paclitaxel to treat patients with metastatic breast cancer.

Athenex: Latest Data Makes A Paradigm Shift In Current Standard Of Care For Cancer Treatment

Athenex's (ATNX) CEO Johnson Lau on Q2 2019 Results - Earnings Call Transcript

Athenex stock crashed Wednesday after the biotech company's cancer treatment, an oral form of paclitaxel, showed mixed results in a Phase 3 test vs. the intravenous form of the drug.

Why This Highflying Biotech With A 50% Gain For 2019 Just Crashed

Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Athenex (ATNX) Report Negative Earnings Next Week? What You Should Know

Athenex (ATNX) shares rose nearly 7% in the last trading session, amid huge volumes.

Athenex (ATNX) in Focus: Stock Moves 6.5% Higher

Anaplan Inc

Chubb

Chewy

Seres Therapeutics

MGM Resorts

Smartsheet

The GuruFocus All-in-One Screener can be used to find insider trades from the past week.

Largest insider trades of the week: June 21

Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.

Athenex Rallies on Positive Early Data on Psoriasis Candidate

Athenex, Inc. (ATNX) CEO Johnson Lau on Q1 2019 Results - Earnings Call Transcript

Aquantia

Bausch Health Companies Inc

Marvell Technology

Despite pressure on the broader market, these stocks bucked the downtrend.

Why Bausch Health Companies, Aquantia, and Athenex Jumped Today

ATNX is a China-based company expanding its US footprint with a State of New York funded R&amp;D space in Buffalo.

Athenex: China-Based Company Developing P-gp Inhibitors

ATNX earnings call for the period ending December 31, 2018.

News for Athenex Stock (ATNX)